Raptor Pharmaceutical (RPTP -1%) says it's licensed pending patents related to the use of...

|About: Raptor Pharmaceutical Corp. (RPTP)|By:, SA News Editor

Raptor Pharmaceutical (RPTP -1%) says it's licensed pending patents related to the use of cysteamine for the treatment of Rett syndrome and associated disorders of methyl-CpG binding protein 2. Under terms of the agreement, RPTP will receive exclusive global rights to develop and commercialize cysteamine and related compounds to treat diseases associated with the disorder.